AKRO - Akero Therapeutics GAAP EPS of -$0.77 beats by $0.10

• Akero Therapeutics press release ( NASDAQ: AKRO ): Q2 GAAP EPS of -$0.77 beats by $0.10 .
• The company believes that its cash, cash equivalents and marketable securities of $180.73M, plus cash from the Hercules facility (if fully drawn), will be sufficient to fund its current operating plan until the third quarter of 2024.
• “During the second quarter of this year we took important steps toward optimizing our capital structure to support the ongoing development of efruxifermin (EFX) by closing a $25 million equity investment from Pfizer and a $100 million term loan facility from Hercules Capital (HTGC),” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero ( AKRO ). “We look forward to reporting Week 24 results of our ongoing Phase 2b HARMONY study in patients with pre-cirrhotic NASH in September of this year, consistent with prior guidance.”

For further details see: